Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Community
/
United States
/
Pharmaceuticals & Biotech
/
Day One Biopharmaceuticals
DAWN
Day One Biopharmaceuticals
High Dependency And Losses Will Hamper Growth But Hope Lingers
AN
AnalystLowTarget
Not Invested
Consensus Narrative from 9 Analysts
Published
25 Aug 25
Updated
25 Aug 25
0
Set Fair Value
0
votes
Share
AnalystLowTarget
's Fair Value
US$16.00
56.4% undervalued
intrinsic discount
25 Aug
US$6.97
1Y
-51.7%
7D
2.3%
Loading
1Y
-51.7%
7D
2.3%
Author's Valuation
US$16.0
56.4% undervalued
intrinsic discount
AnalystLowTarget Fair Value
View Valuation
Narrative
Updates
0
Valuator
Company Info
Notes
AnalystLowTarget Fair Value
US$16.0
56.4% undervalued
intrinsic discount
Future estimation in
3 Years
time period
Past
Future
-183m
268m
2019
2021
2023
2025
2027
2028
Revenue US$267.5m
Earnings US$43.5m
Revenue
Profit Margin
Future PE
Revenue
% p.a.
0
Decrease
Increase
Current revenue growth rate
27.25%
Biotech revenue growth rate
11.91%
Other Inputs & Calculation
Risk Level (Discount Rate)
Our default considers factors like the company's size, volatility, profitablity and country of operation.
Risk Level (Discount Rate)
%
0
Decrease
Increase
Current discount rate
6.78%
Calculation
US$43.47m
Earnings '28
x
47.94x
PE Ratio '28
=
US$2.08b
Market Cap '28
US$2.08b
Market Cap '28
/
107.34m
No. shares '28
=
US$19.42
Share Price '28
US$19.42
Share Price '28
Discounted to 2025 @ 6.78% p.a.
=
US$15.95
Fair Value '25
